Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

医学 脂肪性肝炎 安慰剂 内科学 临床终点 脂肪肝 胃肠病学 超重 体质指数 临床试验 病理 疾病 替代医学
作者
Arun J. Sanyal,Edgar D. Charles,Brent A. Neuschwander‐Tetri,Rohit Loomba,Stephen A. Harrison,Manal F. Abdelmalek,Eric Lawitz,Dina Halegoua‐DeMarzio,Sudeep Kundu,Stephanie Noviello,Yi Luo,Rose Christian
出处
期刊:The Lancet [Elsevier BV]
卷期号:392 (10165): 2705-2717 被引量:541
标识
DOI:10.1016/s0140-6736(18)31785-9
摘要

Background Pegbelfermin (BMS-986036), a PEGylated human fibroblast growth factor 21 (FGF21) analogue, has previously been shown to improve markers of metabolism and liver fibrosis in obese patients with type 2 diabetes. In this phase 2a study, we aimed to evaluate the safety and efficacy of pegbelfermin in patients with non-alcoholic steatohepatitis. Methods In this multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2a study, we recruited adults (aged 21–75 years) with a body-mass index of at least 25 kg/m2, biopsy-confirmed non-alcoholic steatohepatitis (fibrosis stage 1–3), and a hepatic fat fraction of at least 10% when assessed by magnetic resonance imaging-proton density fat fraction. These patients were enrolled at 17 medical centres in the USA. Eligible patients were stratified by type 2 diabetes status and they were randomly assigned (1:1:1) by a computer-based system to receive subcutaneous injections of placebo once a day, 10 mg pegbelfermin once a day, or 20 mg pegbelfermin once a week, all for 16 weeks. Participants, the study team administering treatment, and investigators analysing outcomes (who were independent of the study team and had no further involvement) were masked to treatment groups. The primary outcomes were safety and the absolute change in hepatic fat fraction after 16 weeks of treatment. All patients who were randomly assigned to groups and received the study drug or placebo were included in the primary analyses. This trial was registered with ClinicalTrials.gov, number NCT02413372. Findings Between May 12, 2015, and Aug 4, 2016, 184 overweight or obese patients with non-alcoholic steatohepatitis were screened for study inclusion. Of these, 95 (52%) patients were excluded because they no longer met study criteria and 80 (43%) patients entered the placebo lead-in phase. After further exclusions, 75 (94%) patients were randomly assigned to groups, received at least one dose of treatment (25 patients to receive 10 mg pegbelfermin once a day; 24 patients to receive 20 mg pegbelfermin once a week, and 26 patients to receive placebo), and were included in the primary analysis. A prespecified interim analysis at week 8 showed a greater than expected change in the primary outcome and supported early closing of patient enrolment, since this analysis indicated that the full planned sample size was not needed. We observed a significant decrease in absolute hepatic fat fraction in the group receiving 10 mg pegbelfermin daily (−6·8% vs −1·3%; p=0·0004) and in the group receiving 20 mg pegbelfermin weekly (−5·2% vs −1·3%; p=0·008) compared with the placebo group. Most adverse events were mild; the most common events were diarrhoea in eight (16%) of 49 patients treated with pegbelfermin and two (8%) of 26 patients treated with placebo and nausea in seven (14%) patients treated with pegbelfermin and two (8%) patients treated with placebo. There were no deaths, discontinuations due to adverse events, or treatment-related serious adverse events. Interpretation Treatment with subcutaneously administered pegbelfermin for 16 weeks was generally well tolerated and significantly reduced hepatic fat fraction in patients with non-alcoholic steatohepatitis. Further study of pegbelfermin is warranted in patients with non-alcoholic steatohepatitis. Additional studies that use liver biopsies would allow for the assessment of pegbelfermin's effects on liver histology. Moreover, further studies should allow assessments of the safety and effectiveness of pegbelfermin in a larger number of patients. Funding Bristol-Myers Squibb.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小孙大王发布了新的文献求助20
刚刚
桐桐的应助被vicky采纳,获得30
刚刚
Orange的应助被KKIII采纳,获得10
2秒前
小蘑菇的应助被Lizhenhua采纳,获得10
2秒前
机智的白卉的应助被十面埋伏采纳,获得10
2秒前
初初初啊发布了新的文献求助10
2秒前
2秒前
3秒前
yyyyy发布了新的文献求助30
3秒前
ghost完成签到 ,获得积分10
5秒前
5秒前
圆满的鱼完成签到,获得积分10
5秒前
5秒前
5秒前
6秒前
7秒前
7秒前
8秒前
lxx完成签到 ,获得积分10
9秒前
小羊完成签到 ,获得积分10
10秒前
木子发布了新的文献求助10
10秒前
子曰完成签到,获得积分10
11秒前
科研通AI6.2的应助被一只眠羊采纳,获得10
11秒前
11秒前
天才c完成签到,获得积分10
12秒前
114514发布了新的文献求助10
12秒前
12秒前
12秒前
芒绽完成签到 ,获得积分10
12秒前
迷路的笑槐完成签到,获得积分10
12秒前
12秒前
专注凌柏发布了新的文献求助10
13秒前
13秒前
十面埋伏完成签到,获得积分10
13秒前
13秒前
orixero的应助被虚拟的如霜采纳,获得10
13秒前
bkagyin的应助被chen采纳,获得10
14秒前
14秒前
学术小垃圾完成签到,获得积分10
14秒前
Jasper的应助被wyz采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165074
求助须知:如何正确求助?哪些是违规求助? 9558738
关于积分的说明 21747291
捐赠科研通 7755624
什么是DOI,文献DOI怎么找? 3428780
关于科研通互助平台的介绍 2553162
邀请新用户注册赠送积分活动 2473361